AbbVie submits BLA for etentamig to FDA for relapsed/refractory multiple myeloma
AbbVie announced the submission of a Biologics License Application for etentamig, a second-generation BCMA x CD3 bispecific antibody, to the U.S. FDA for adults with relapsed or refractory multiple myeloma. The company cited Phase 3 CERVINO study results showing a 74.0% overall response rate versus 45.7% for investigator's choice and a 60% risk reduction in progression-free survival.
Primary source
Company press release (PR Newswire), October 27, 2026
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
Machine-summarized from the source above; not independently reported. How we use automation